Marker Therapeutics, Inc. last reported quarterly results on Nov 14, 2025, for Q3 FY2025 (the quarter ended Sep 30, 2025): revenue of $1.2 million (-36.0% year over year) and diluted EPS of -$0.12. It usually reports 45 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 14, 2025
45 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1
-36.0%
|
-2
+13.4%
|
-0.12
+53.8%
|
|
Nov 14, 2024
45 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
2
+647.7%
|
-2
+22.6%
|
-0.26
+23.5%
|
|
Aug 14, 2024
45 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
May 15, 2024
45 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
|
Nov 9, 2023
40 days after quarter end
|
—
ended Sep 30, 2023
|
—
|
—
|
—
|
|
Aug 14, 2023
45 days after quarter end
|
—
ended Jun 30, 2023
|
—
|
—
|
—
|
|
Nov 10, 2022
41 days after quarter end
|
—
ended Sep 30, 2022
|
—
|
—
|
—
|
|
Aug 11, 2022
42 days after quarter end
|
—
ended Jun 30, 2022
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MRKR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1094038
- Former names
- TAPIMMUNE INC. (until Oct 17, 2018); TAPIMMUNE INC (until Jun 29, 2017); GENEMAX CORP (until Jun 28, 2007); EDUVERSE COM (until Jun 17, 2002)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.